GlaxoSmithKline (GSK)
News
| May 25 | 4 Stocks Buffett May Be Buying in Europe Investor Place |
| May 25 | Is This Dow Heavyweight a Value Trap? Fool |
| May 25 | The Fool's Guide to Buying U.K. Retail Bonds Fool |
| May 24 | Finding a Pathway to Approval Fool |
| May 23 | Pfizer's Success Tied Closely to Pristiq Fool |
| May 23 | $GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled. by OysterX |
| May 23 | GlaxoSmithKline Amends HGS Tender Offer to Address Poison Pill, Requires HGS to Redee... |
| May 22 | Buffett and Woodford Agree on This One! Fool |
| May 22 | Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guida... |
| May 21 | 20 Giants for a 6% Dividend Yield Fool |
| May 17 | @xjun "totally betrayed" $AMRN says: "Sorry, it's not personal. Look at some of my neighbours: $ONTY, $SPPI, $NVAX, $GSK, $TEVA, $CELG ..." by mitrado |
| May 17 | Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15. by OysterX |
| May 17 | News related to $GSK, currently 0.0% since open: 'Prestige Brands posts small fiscal 4Q loss' http://stks.co/3s9V by TradeBot |
| May 17 | $GSK Trametinib also in the spotlight at ASCO '12 with six presentations over 4 days. http://stks.co/3roL by abubnic |
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Major
GlaxoSmithKline plc, often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's third largest pharmaceutical company measured by revenues (after Johnson & Johnson and Pfizer). It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.As one of the world's top prescription drug makers, GlaxoSmithKline enjoys annual revenues that exceed 13.2 billion. GSK was formed in 2000 by the merger of GlaxoWellcome plc (formed from the acquisition of Wellcome plc by Glaxo plc), and SmithKline Beecham plc (from the merger of Beecham plc, and SmithKlineBeckman Corporation). GlaxoSmithKline plc was founded in 1999 and is headquartered in Brentford, United Kingdom.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). GlaxoSmithKline is up 7.94% over the last year vs S&P 500 Total Return up 2.57%, Pfizer up 10.35%, and Novartis down 12.79%.
- GSK Total Returns
- ^SPXTR Total Returns
- PFE Total Returns
- NVS Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these GSK related companies
Pro Strategies Featuring GSK
Did GlaxoSmithKline make it into our Pro Portfolio Strategies?
GSK Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other GSK Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.28 | +0.04 | +0.09% | 111.75B |
| GSIT | 4.20 | +0.00 | +0.00% | 120.25M |
| GSB | 2.15 | +0.03 | +1.42% | 39.15M |
| GSAT | 0.4049 | +0.03 | +6.58% | 120.61M |
| GS | 96.70 | -0.16 | -0.17% | 47.86B |
| GRZ | 3.29 | +0.07 | +2.17% | 195.89M |
| GRRF | 3.11 | +0.00 | +0.00% | 70.69M |
| GRO | 1.07 | +0.00 | +0.00% | 59.26M |
| GRMN | 43.19 | -0.53 | -1.21% | 8.406B |
| GRA | 52.56 | -1.03 | -1.92% | 3.886B |
